The "Hope for Oklahoma Patients Act" establishes a framework for providing individualized investigational treatments to eligible patients with life-threatening or severely debilitating illnesses. The bill defines key terms, including "eligible facility," "eligible patient," and "individualized investigational treatment," and outlines the criteria that patients must meet to qualify for such treatments. It emphasizes that the act is voluntary for manufacturers and payors, meaning they are not required to provide these treatments or coverage. Additionally, the act grants certain immunities from civil liability to manufacturers and health care providers who comply with its provisions.

The legislation also includes provisions to protect health care providers from penalties related to their recommendations for individualized investigational treatments and prohibits state entities from obstructing patient access to these treatments. Importantly, it clarifies that if a patient's death is caused by the investigational treatment, their estate will not be liable for remaining debts after insurance payments, although this does not extend to non-experimental treatments. The act is set to take effect on November 1, 2026.